Dear Colleagues,
let me invite you to the ECCO'21 Congress - which has now been decided to feature an exceptional summer-time congress experience in Copenhagen, July 7-10, 2021 in order to minimise any risk related to the COVID-19 pandemic.
With the beginning of the new decade, 2021 will be a crucial year to look into "IBD precise".
With its steadily increasing number of participants, the ECCO Congress has become the leading world congress for Inflammatory Bowel Diseases and we look forward to welcoming you to a highly diverse programme with a major focus on precision medicine for IBD.
Among the highlights of the 2021 Scientific Programme are topics like direct comparison and combination of drugs. In 2021, we should be able to determine the role of artificial intelligence in IBD, to choose the safest therapeutic option in an era of multiple medications and to tailor therapeutic strategies to patients' profile such as age.
Top specialists will also provide new insights on the real burden of IBD, the optimal managment of disease complications, the best way to monitor our patients and the ultimate therapeutic goals.